Loading…

Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease

The APOE ɛ4 gene variant is the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE ɛ3 conventionally is considered as ‘risk neutral’ although APOE ɛ3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Alzheimer's disease 2019-01, Vol.71 (4), p.1217-1231
Main Authors: Patra, Kalicharan, Giannisis, Andreas, Edlund, Anna K., Sando, Sigrid Botne, Lauridsen, Camilla, Berge, Guro, Grøntvedt, Gøril Rolfseng, Bråthen, Geir, White, Linda R., Nielsen, Henrietta M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c384t-c8916f536ef9fe0073e27d85cad85b6f6d3ba018fdbb3a8a991ffe4a26eec8fd3
cites cdi_FETCH-LOGICAL-c384t-c8916f536ef9fe0073e27d85cad85b6f6d3ba018fdbb3a8a991ffe4a26eec8fd3
container_end_page 1231
container_issue 4
container_start_page 1217
container_title Journal of Alzheimer's disease
container_volume 71
creator Patra, Kalicharan
Giannisis, Andreas
Edlund, Anna K.
Sando, Sigrid Botne
Lauridsen, Camilla
Berge, Guro
Grøntvedt, Gøril Rolfseng
Bråthen, Geir
White, Linda R.
Nielsen, Henrietta M.
description The APOE ɛ4 gene variant is the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE ɛ3 conventionally is considered as ‘risk neutral’ although APOE ɛ3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. Here we assessed the distribution of monomers, homodimers and heterodimers in plasma from control subjects and patients with mild cognitive impairment (MCI) and AD with either a homozygous APOE ɛ3 (n = 31 control subjects, and n = 14 MCI versus n = 5 AD patients) or APOE ɛ4 genotype (n = 1 control subject, n = 21 MCI and n = 7 AD patients). Total plasma apoE levels were lower in APOE ɛ4-carriers and overall correlated significantly to CSF Aβ42, p(Thr181)-tau and t-tau levels. Apolipoprotein E dimers were only observed in the APOE ɛ3-carriers and associated with total plasma apoE levels, negatively correlated to apoE monomers, but were unrelated to plasma homocysteine levels. Importantly, the APOE ɛ3-carrying AD patients versus controls exhibited a significant decrease in apoE homodimers (17.8±9.6% versus 26.7±6.3%, p = 0.025) paralleled by an increase in apoE monomers (67.8±18.3% versus 48.5±11.2%, p = 0.008). In the controls, apoE monomers and heterodimers were significantly associated with plasma triglycerides; the apoE heterodimers were also associated with levels of high-density lipoprotein cholesterol. The physiological relevance of apoE dimer formation needs to be further investigated, though the distribution of apoE in monomers and dimers appears to be of relevance to AD in APOE ɛ3 subjects.
doi_str_mv 10.3233/JAD-190175
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_DiVA_org_su_175908</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.3233_JAD-190175</sage_id><sourcerecordid>2290964851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-c8916f536ef9fe0073e27d85cad85b6f6d3ba018fdbb3a8a991ffe4a26eec8fd3</originalsourceid><addsrcrecordid>eNptkd1KxDAQhYMo_t_4AFLwQhGrSbNpk8uy6y-Ki6h4F9J2opW2qclW0Stfw9fzScy66wrizWQYPs7kzEFog-B9GlF6cJYOQiIwSdgcWiY8YSEXmM_7nvIkjHiSLKEV5x4xxhSLZBEtUcKiHmHxMrobVsrVKkhbU5Wtaa0ZQdkEh8GFaUwNNlBNEQzKcTe0RpcVfE-uoIJn1eQQjEyQVm8PMEY-3z-chx0oB2toQavKwfr0XUU3R4fX_ZPw_PL4tJ-ehznlvVGYc0FizWgMWmjAOKEQJQVnufIli3Vc0ExhwnWRZVRxJQTRGnoqigFyP6WraG-i616g7TLZ2rJW9lUaVcpBeZtKY--l66S_jj-Kx3cmuHf61IEbybp0OVSVasB0TkaRwCLucUY8uvUHfTSdbbwZGVHMWMwFHwvuTqjcGucs6NkPCJbjeKSPR07i8fDmVLLLaihm6E8eHtieulH38LvvH6kvkhyXQA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2305568988</pqid></control><display><type>article</type><title>Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Patra, Kalicharan ; Giannisis, Andreas ; Edlund, Anna K. ; Sando, Sigrid Botne ; Lauridsen, Camilla ; Berge, Guro ; Grøntvedt, Gøril Rolfseng ; Bråthen, Geir ; White, Linda R. ; Nielsen, Henrietta M.</creator><contributor>Nacmias, Benedatta</contributor><creatorcontrib>Patra, Kalicharan ; Giannisis, Andreas ; Edlund, Anna K. ; Sando, Sigrid Botne ; Lauridsen, Camilla ; Berge, Guro ; Grøntvedt, Gøril Rolfseng ; Bråthen, Geir ; White, Linda R. ; Nielsen, Henrietta M. ; Nacmias, Benedatta</creatorcontrib><description>The APOE ɛ4 gene variant is the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE ɛ3 conventionally is considered as ‘risk neutral’ although APOE ɛ3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. Here we assessed the distribution of monomers, homodimers and heterodimers in plasma from control subjects and patients with mild cognitive impairment (MCI) and AD with either a homozygous APOE ɛ3 (n = 31 control subjects, and n = 14 MCI versus n = 5 AD patients) or APOE ɛ4 genotype (n = 1 control subject, n = 21 MCI and n = 7 AD patients). Total plasma apoE levels were lower in APOE ɛ4-carriers and overall correlated significantly to CSF Aβ42, p(Thr181)-tau and t-tau levels. Apolipoprotein E dimers were only observed in the APOE ɛ3-carriers and associated with total plasma apoE levels, negatively correlated to apoE monomers, but were unrelated to plasma homocysteine levels. Importantly, the APOE ɛ3-carrying AD patients versus controls exhibited a significant decrease in apoE homodimers (17.8±9.6% versus 26.7±6.3%, p = 0.025) paralleled by an increase in apoE monomers (67.8±18.3% versus 48.5±11.2%, p = 0.008). In the controls, apoE monomers and heterodimers were significantly associated with plasma triglycerides; the apoE heterodimers were also associated with levels of high-density lipoprotein cholesterol. The physiological relevance of apoE dimer formation needs to be further investigated, though the distribution of apoE in monomers and dimers appears to be of relevance to AD in APOE ɛ3 subjects.</description><identifier>ISSN: 1387-2877</identifier><identifier>ISSN: 1875-8908</identifier><identifier>EISSN: 1875-8908</identifier><identifier>DOI: 10.3233/JAD-190175</identifier><identifier>PMID: 31524156</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Alzheimer's disease ; Apolipoprotein A ; Apolipoprotein A-II ; Apolipoprotein E ; Apolipoproteins ; biomarkers ; Body fluids ; Cerebrospinal fluid ; Cholesterol ; Cognitive ability ; Dementia ; Dimers ; Genotypes ; Health risk assessment ; Homocysteine ; Monomers ; Plasma ; Risk analysis ; Risk factors ; Tau protein ; Triglycerides</subject><ispartof>Journal of Alzheimer's disease, 2019-01, Vol.71 (4), p.1217-1231</ispartof><rights>2019 – IOS Press and the authors. All rights reserved</rights><rights>Copyright IOS Press BV 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-c8916f536ef9fe0073e27d85cad85b6f6d3ba018fdbb3a8a991ffe4a26eec8fd3</citedby><cites>FETCH-LOGICAL-c384t-c8916f536ef9fe0073e27d85cad85b6f6d3ba018fdbb3a8a991ffe4a26eec8fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31524156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-175908$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>Nacmias, Benedatta</contributor><creatorcontrib>Patra, Kalicharan</creatorcontrib><creatorcontrib>Giannisis, Andreas</creatorcontrib><creatorcontrib>Edlund, Anna K.</creatorcontrib><creatorcontrib>Sando, Sigrid Botne</creatorcontrib><creatorcontrib>Lauridsen, Camilla</creatorcontrib><creatorcontrib>Berge, Guro</creatorcontrib><creatorcontrib>Grøntvedt, Gøril Rolfseng</creatorcontrib><creatorcontrib>Bråthen, Geir</creatorcontrib><creatorcontrib>White, Linda R.</creatorcontrib><creatorcontrib>Nielsen, Henrietta M.</creatorcontrib><title>Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease</title><title>Journal of Alzheimer's disease</title><addtitle>J Alzheimers Dis</addtitle><description>The APOE ɛ4 gene variant is the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE ɛ3 conventionally is considered as ‘risk neutral’ although APOE ɛ3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. Here we assessed the distribution of monomers, homodimers and heterodimers in plasma from control subjects and patients with mild cognitive impairment (MCI) and AD with either a homozygous APOE ɛ3 (n = 31 control subjects, and n = 14 MCI versus n = 5 AD patients) or APOE ɛ4 genotype (n = 1 control subject, n = 21 MCI and n = 7 AD patients). Total plasma apoE levels were lower in APOE ɛ4-carriers and overall correlated significantly to CSF Aβ42, p(Thr181)-tau and t-tau levels. Apolipoprotein E dimers were only observed in the APOE ɛ3-carriers and associated with total plasma apoE levels, negatively correlated to apoE monomers, but were unrelated to plasma homocysteine levels. Importantly, the APOE ɛ3-carrying AD patients versus controls exhibited a significant decrease in apoE homodimers (17.8±9.6% versus 26.7±6.3%, p = 0.025) paralleled by an increase in apoE monomers (67.8±18.3% versus 48.5±11.2%, p = 0.008). In the controls, apoE monomers and heterodimers were significantly associated with plasma triglycerides; the apoE heterodimers were also associated with levels of high-density lipoprotein cholesterol. The physiological relevance of apoE dimer formation needs to be further investigated, though the distribution of apoE in monomers and dimers appears to be of relevance to AD in APOE ɛ3 subjects.</description><subject>Alzheimer's disease</subject><subject>Apolipoprotein A</subject><subject>Apolipoprotein A-II</subject><subject>Apolipoprotein E</subject><subject>Apolipoproteins</subject><subject>biomarkers</subject><subject>Body fluids</subject><subject>Cerebrospinal fluid</subject><subject>Cholesterol</subject><subject>Cognitive ability</subject><subject>Dementia</subject><subject>Dimers</subject><subject>Genotypes</subject><subject>Health risk assessment</subject><subject>Homocysteine</subject><subject>Monomers</subject><subject>Plasma</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Tau protein</subject><subject>Triglycerides</subject><issn>1387-2877</issn><issn>1875-8908</issn><issn>1875-8908</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNptkd1KxDAQhYMo_t_4AFLwQhGrSbNpk8uy6y-Ki6h4F9J2opW2qclW0Stfw9fzScy66wrizWQYPs7kzEFog-B9GlF6cJYOQiIwSdgcWiY8YSEXmM_7nvIkjHiSLKEV5x4xxhSLZBEtUcKiHmHxMrobVsrVKkhbU5Wtaa0ZQdkEh8GFaUwNNlBNEQzKcTe0RpcVfE-uoIJn1eQQjEyQVm8PMEY-3z-chx0oB2toQavKwfr0XUU3R4fX_ZPw_PL4tJ-ehznlvVGYc0FizWgMWmjAOKEQJQVnufIli3Vc0ExhwnWRZVRxJQTRGnoqigFyP6WraG-i616g7TLZ2rJW9lUaVcpBeZtKY--l66S_jj-Kx3cmuHf61IEbybp0OVSVasB0TkaRwCLucUY8uvUHfTSdbbwZGVHMWMwFHwvuTqjcGucs6NkPCJbjeKSPR07i8fDmVLLLaihm6E8eHtieulH38LvvH6kvkhyXQA</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Patra, Kalicharan</creator><creator>Giannisis, Andreas</creator><creator>Edlund, Anna K.</creator><creator>Sando, Sigrid Botne</creator><creator>Lauridsen, Camilla</creator><creator>Berge, Guro</creator><creator>Grøntvedt, Gøril Rolfseng</creator><creator>Bråthen, Geir</creator><creator>White, Linda R.</creator><creator>Nielsen, Henrietta M.</creator><general>SAGE Publications</general><general>IOS Press BV</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG7</scope></search><sort><creationdate>20190101</creationdate><title>Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease</title><author>Patra, Kalicharan ; Giannisis, Andreas ; Edlund, Anna K. ; Sando, Sigrid Botne ; Lauridsen, Camilla ; Berge, Guro ; Grøntvedt, Gøril Rolfseng ; Bråthen, Geir ; White, Linda R. ; Nielsen, Henrietta M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-c8916f536ef9fe0073e27d85cad85b6f6d3ba018fdbb3a8a991ffe4a26eec8fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alzheimer's disease</topic><topic>Apolipoprotein A</topic><topic>Apolipoprotein A-II</topic><topic>Apolipoprotein E</topic><topic>Apolipoproteins</topic><topic>biomarkers</topic><topic>Body fluids</topic><topic>Cerebrospinal fluid</topic><topic>Cholesterol</topic><topic>Cognitive ability</topic><topic>Dementia</topic><topic>Dimers</topic><topic>Genotypes</topic><topic>Health risk assessment</topic><topic>Homocysteine</topic><topic>Monomers</topic><topic>Plasma</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Tau protein</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patra, Kalicharan</creatorcontrib><creatorcontrib>Giannisis, Andreas</creatorcontrib><creatorcontrib>Edlund, Anna K.</creatorcontrib><creatorcontrib>Sando, Sigrid Botne</creatorcontrib><creatorcontrib>Lauridsen, Camilla</creatorcontrib><creatorcontrib>Berge, Guro</creatorcontrib><creatorcontrib>Grøntvedt, Gøril Rolfseng</creatorcontrib><creatorcontrib>Bråthen, Geir</creatorcontrib><creatorcontrib>White, Linda R.</creatorcontrib><creatorcontrib>Nielsen, Henrietta M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Stockholms universitet</collection><jtitle>Journal of Alzheimer's disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patra, Kalicharan</au><au>Giannisis, Andreas</au><au>Edlund, Anna K.</au><au>Sando, Sigrid Botne</au><au>Lauridsen, Camilla</au><au>Berge, Guro</au><au>Grøntvedt, Gøril Rolfseng</au><au>Bråthen, Geir</au><au>White, Linda R.</au><au>Nielsen, Henrietta M.</au><au>Nacmias, Benedatta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease</atitle><jtitle>Journal of Alzheimer's disease</jtitle><addtitle>J Alzheimers Dis</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>71</volume><issue>4</issue><spage>1217</spage><epage>1231</epage><pages>1217-1231</pages><issn>1387-2877</issn><issn>1875-8908</issn><eissn>1875-8908</eissn><abstract>The APOE ɛ4 gene variant is the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE ɛ3 conventionally is considered as ‘risk neutral’ although APOE ɛ3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. Here we assessed the distribution of monomers, homodimers and heterodimers in plasma from control subjects and patients with mild cognitive impairment (MCI) and AD with either a homozygous APOE ɛ3 (n = 31 control subjects, and n = 14 MCI versus n = 5 AD patients) or APOE ɛ4 genotype (n = 1 control subject, n = 21 MCI and n = 7 AD patients). Total plasma apoE levels were lower in APOE ɛ4-carriers and overall correlated significantly to CSF Aβ42, p(Thr181)-tau and t-tau levels. Apolipoprotein E dimers were only observed in the APOE ɛ3-carriers and associated with total plasma apoE levels, negatively correlated to apoE monomers, but were unrelated to plasma homocysteine levels. Importantly, the APOE ɛ3-carrying AD patients versus controls exhibited a significant decrease in apoE homodimers (17.8±9.6% versus 26.7±6.3%, p = 0.025) paralleled by an increase in apoE monomers (67.8±18.3% versus 48.5±11.2%, p = 0.008). In the controls, apoE monomers and heterodimers were significantly associated with plasma triglycerides; the apoE heterodimers were also associated with levels of high-density lipoprotein cholesterol. The physiological relevance of apoE dimer formation needs to be further investigated, though the distribution of apoE in monomers and dimers appears to be of relevance to AD in APOE ɛ3 subjects.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>31524156</pmid><doi>10.3233/JAD-190175</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1387-2877
ispartof Journal of Alzheimer's disease, 2019-01, Vol.71 (4), p.1217-1231
issn 1387-2877
1875-8908
1875-8908
language eng
recordid cdi_swepub_primary_oai_DiVA_org_su_175908
source SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)
subjects Alzheimer's disease
Apolipoprotein A
Apolipoprotein A-II
Apolipoprotein E
Apolipoproteins
biomarkers
Body fluids
Cerebrospinal fluid
Cholesterol
Cognitive ability
Dementia
Dimers
Genotypes
Health risk assessment
Homocysteine
Monomers
Plasma
Risk analysis
Risk factors
Tau protein
Triglycerides
title Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T07%3A56%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20Apolipoprotein%20E%20Monomer%20and%20Dimer%20Profile%20and%20Relevance%20to%20Alzheimer%E2%80%99s%20Disease&rft.jtitle=Journal%20of%20Alzheimer's%20disease&rft.au=Patra,%20Kalicharan&rft.date=2019-01-01&rft.volume=71&rft.issue=4&rft.spage=1217&rft.epage=1231&rft.pages=1217-1231&rft.issn=1387-2877&rft.eissn=1875-8908&rft_id=info:doi/10.3233/JAD-190175&rft_dat=%3Cproquest_swepu%3E2290964851%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c384t-c8916f536ef9fe0073e27d85cad85b6f6d3ba018fdbb3a8a991ffe4a26eec8fd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2305568988&rft_id=info:pmid/31524156&rft_sage_id=10.3233_JAD-190175&rfr_iscdi=true